Compare SWK & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWK | BBIO |
|---|---|---|
| Founded | 1843 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 12.7B |
| IPO Year | 2009 | 2019 |
| Metric | SWK | BBIO |
|---|---|---|
| Price | $88.69 | $86.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 25 |
| Target Price | $84.00 | ★ $86.33 |
| AVG Volume (30 Days) | 1.7M | ★ 3.6M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.38% | N/A |
| EPS Growth | ★ 35.90 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $15,130,400,000.00 | $502,076,000.00 |
| Revenue This Year | $1.56 | $89.45 |
| Revenue Next Year | $2.10 | $73.78 |
| P/E Ratio | $222.83 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $61.90 | $42.09 |
| 52 Week High | $95.16 | $93.42 |
| Indicator | SWK | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 74.00 |
| Support Level | $72.88 | $62.93 |
| Resistance Level | $94.27 | N/A |
| Average True Range (ATR) | 2.98 | 3.18 |
| MACD | -0.65 | 1.78 |
| Stochastic Oscillator | 44.48 | 73.02 |
Stanley Black & Decker Inc offers hand tools, power tools, outdoor products, engineered fastening solutions, and related accessories. The company operates in two reportable business segments: Tools & Outdoor and Engineered Fastening. The majority of its revenue is generated from the Tools & Outdoor segment, which is comprised of the Power Tools Group (PTG), Hand Tools, Accessories and Storage (HTAS), and Outdoor Power Equipment (Outdoor) product lines. This segment's product offerings include drills, impact wrenches and drivers, grinders, saws, hammers, demolition tools, clamps, vises, knives, edge trimmers, lawn mowers, etc., which are offered through brands like Hustler, Dewalt, Craftsman, Stanley, and others. Geographically, the firm derives maximum revenue from the United States.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.